



SUNESIS

Sunesis to Present at Upcoming Investor Conferences

August 31, 2017

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the company will present at two upcoming investor conferences.

Daniel Swisher, Chief Executive Officer of Sunesis, will present at the Wells Fargo Securities 2017 Healthcare Conference on Thursday, September 7, 2017 at 1:05 PM Eastern Time at The Westin Boston Waterfront hotel in Boston, MA.

Mr. Swisher will also present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 1:05 PM Eastern Time at the Intercontinental New York Barclay Hotel in New York City.

Live webcasts of the presentations will be available on the Sunesis website at <http://ir.sunesis.com>. A replay of each webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the future treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor, SNS-062, treats ibrutinib-resistant chronic lymphocytic leukemia. Sunesis is also supporting investigator-led studies of vosaroxin in acute myeloid leukemia.

For additional information on Sunesis, please visit www.sunesis.com.

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

Investor and Media Inquiries: Maeve Conneighton
Argot Partners
212-600-1902
Dan Swisher
Sunesis Pharmaceuticals Inc.
650-266-3715

[Primary Logo](#)

Sunesis Pharmaceuticals Inc